Ionis Pharmaceuticals: The Heartbreak Is Priced In
Sentiment Analysis
The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis’s wholly owned core assets.
Tryngolza is the main value driver, supported by strong triglyceride and pancreatitis data and a large sHTG market.
Dawnzera's upcoming pipeline catalysts and $1.9B of liquidity support growth and a credible path to 2028 breakeven.
Despite reimbursement, competition, and execution risks, Ionis’s ~$9B valuation offers attractive upside, supporting a speculative BUY.
I initiate coverage of Ionis Pharmaceuticals, Inc. (IONS) with a Buy rating.
Recently, the shares sold off following the two July 2026 setbacks: a) the phase 3 CARDIO-TTRansform trial of
Source: Seeking Alpha
個別の投資に関する推奨やアドバイスを提供することを意図しておりません。ここで述べられている意見や見解は、あくまでも各記事の個人的見解です。